New Delhi: Moderna has requested approval for restricted emergency use authorisation for it’s COVID-19 vaccine from the Drug Controller General of India (DCGI), official sources told media on Tuesday. Moderna has also informed that the US Government has agreed to donate a certain number of doses of its COVID-19 vaccine through COVAX to India for use and has sought approval from the Central Drugs Standard Control Organisation (CDSCO) for these vaccines. Moderna is said to be 94 per cent effective against Covid.
Like Pfizer, Moderna is an mRNA vaccine which was granted approval by the World Health Organisation for emergency use on April 30.
The World Health Organisation has said that the Moderna vaccine has been shown to have an efficacy of approximately 94.1 per cent in protecting against COVID-19, starting 14 days after the first dose. The WHO Strategic Advisory Group of Experts (SAGE) has recommended the use of the Moderna mRNA-1273 vaccine at a schedule of two doses (100 µg, 0.5 ml each) 28 days apart. If necessary, the interval between the doses may be extended to 42 days. WHO has also added that based on the evidence so far, the new variants of coronavirus, including the Alpha and Beta variants, do not alter the effectiveness of the Moderna mRNA vaccine.
The vaccine works by giving cells temporary instructions to make the coronavirus spike protein. The protein is found on the surface of the COVID-19 virus.
Recently, Pfizer CEO Albert Bourla had said that the company’s vaccine may soon be available in India as the process of its approval is in the “final stages”.
“Pfizer is now in the final stages to get approval for COVID-19 vaccine in India. I hope very soon we will finalise an agreement with the government,” Mr Bourla had said.
The rollout of foreign vaccines has been stalled over their condition that India waives indemnity from liability in case of an adverse effect.